14th European ISSX Meeting

June, 26-29, Cologne, Germany.

We will be exhibiting and presenting two posters at the 14th European ISSX Meeting in Cologne, Germany 26-29 June. 

Poster No P33 – Session 1: Tuesday, June 27 – 13:00 to 13:30

Title: Using 14C radiolabelled clinical studies to explore and evaluate factors influencing oral exposure.

Poster No P48 – Session 1:  Tuesday, June 27 – 13:30 to 14:00

Title: Cocktail approach for assessing CYP450 drug-drug interaction liabilities including assessment of differential inhibition of liver and gut CYP3A4.

Iain Shaw, Director, 14-C Enabled Drug Development will be attending and if you wish to discuss human ADME and 14c radiolabelled study support, we will be located at booth 211.

The 11th International ISSX Meeting will bring together individuals who are actively working on drug/xenobiotic research in diverse fields including basic and clinical pharmacology and therapeutics, toxicology, oncology and genetics. 

With over 30 years’ experience, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA/MAA submissions.

To find out more, contact Iain directly via email: iain.shaw@quotientclinical.com or call +44 750 010 4486